SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.

SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 May 10; 33(14):1601-8.

View in: PubMed

subject areas

Aged
Androgen Antagonists
Anilides
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Hormonal
Biomarkers, Tumor
Drug Administration Schedule
Gonadotropin-Releasing Hormone
Humans
Logistic Models
Male
Middle Aged
Neoplasm Staging
Neoplastic Cells, Circulating
Nitriles
Prostate-Specific Antigen
Prostatic Neoplasms
Receptor, IGF Type 1
Tosyl Compounds
Treatment Outcome

authors with profiles

Michael B. Lilly